In the BioHarmony Drug Report Database

"Preview" Icon

Solifenacin

Vesicare, Vesicare Ls (solifenacin) is a small molecule pharmaceutical. Solifenacin was first approved as Vesicare on 2004-11-19. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3 and muscarinic acetylcholine receptor M2. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1. Vesicare’s patent is valid until 2031-05-18 (FDA).

 

Trade Name

 

Vesicare, Vesicare Ls
 

Common Name

 

solifenacin
 

ChEMBL ID

 

CHEMBL1734
 

Indication

 

overactive urinary bladder, urge urinary incontinence
 

Drug Class

 

Muscarinic receptor antagonists

Image (chem structure or protein)

Solifenacin structure rendering